Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $1.8 million.

  • Sanara MedTech's Interest Expenses rose 9600.58% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 19227.34%. This contributed to the annual value of $3.1 million for FY2024, which is 55752.56% up from last year.
  • Sanara MedTech's Interest Expenses amounted to $1.8 million in Q3 2025, which was up 9600.58% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Interest Expenses registered a high of $1.8 million during Q3 2025, and its lowest value of $6.0 during Q1 2023.
  • Moreover, its 5-year median value for Interest Expenses was $277409.5 (2023), whereas its average is $629742.9.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 9148.91% in 2021, then skyrocketed by 445550000.0% in 2024.
  • Over the past 5 years, Sanara MedTech's Interest Expenses (Quarter) stood at $711.0 in 2021, then skyrocketed by 15600.42% to $111630.0 in 2022, then skyrocketed by 157.53% to $287483.0 in 2023, then surged by 348.42% to $1.3 million in 2024, then skyrocketed by 41.03% to $1.8 million in 2025.
  • Its Interest Expenses was $1.8 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.3 million in Q1 2025.